Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies

Maintaining bone health remains a clinical challenge in patients with prostate cancer (PC) who are at risk of developing metastatic bone disease and increased bone loss due to hormone ablation therapy. In patients with cancer-treatment induced bone loss (CTIBL), antiresorptive agents have been shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Todenhöfer, Tilman, Stenzl, Arnulf, Hofbauer, Lorenz C., Rachner, Tilman D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329828/
https://www.ncbi.nlm.nih.gov/pubmed/25802521
http://dx.doi.org/10.1155/2015/838202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329828/
https://www.ncbi.nlm.nih.gov/pubmed/25802521
http://dx.doi.org/10.1155/2015/838202

Ejemplares similares